When will the METICORTELONE patents expire, and when will generic METICORTELONE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	METICORTELONE	prednisolone acetate	INJECTABLE;INJECTION	010255-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 26, 2026

Meticortelone Investment Scenario and Patent/Regulatory Fundamentals (Exclusivity, Generic Risk, and Commercial Outlook)

Meticortelone is a glucocorticoid (systemic corticosteroid) formulation sold in multiple markets, but the investment case depends on (1) whether the product is still protected by enforceable patents or regulatory exclusivity in each target geography, (2) whether additional formulation/method patents exist beyond the original marketing authorization, and (3) how exposed the brand is to authorized generics or discounting. For a credible investment and licensing posture, the controlling variables are the Orange Book-equivalent status in the US (if applicable), SPC/patent coverage in the EU, and local generic penetration in the licensed territories.

This analysis compiles the investment-relevant fundamentals that typically drive valuation for a branded corticosteroid where patent estates may be thin by now and where commercial performance often tracks tendering, reimbursement, and wholesale channel share more than premium pricing power.

What is Meticortelone, what indications does it cover, and what’s the commercial demand profile?

Meticortelone is used for inflammatory and allergic conditions where systemic glucocorticoid therapy is indicated. Revenue dynamics in systemic corticosteroids are usually driven by:

payer coverage and reimbursement rules
tenders and hospital formularies
switching to lower-priced generics
safety-driven prescriber preferences and guideline alignment

Indication breadth and demand sensitivity

Systemic corticosteroids tend to have broad clinical use but high price sensitivity once generics establish. Demand also correlates with:

frequency of acute exacerbation treatment
physician prescribing patterns for short courses
seasonal variation in allergic respiratory disease (where relevant)

Key investment implication

If meticortelone remains primarily a “generic-like brand” in most markets, the investment case shifts from patent-driven monopoly margins to distribution economics and contract wins.

What patents protect Meticortelone, and how many patent families typically cover systemic corticosteroids?

A systemic corticosteroid with long market history often has a patent estate structure that breaks into:

active-ingredient process/compound patents (often long expired for older molecules)
formulation patents (salts, particle engineering, excipients)
dosing regimens or method-of-use patents
packaging/manufacturing-process patents

Patent-family pattern for corticosteroids

For older corticosteroids, the enforceable value usually concentrates in later-life patents on:

specific formulations (release characteristics, solvent systems, stability-enhanced blends)
improved manufacturing methods
combination products (if any)

How to underwrite “patent strength”

In practice, meticortelone’s patent value hinges on whether any of the following are still active in the jurisdictions that matter commercially:

enforceable composition/formulation claims
enforceable method-of-use claims that map to current labeling
enforceable secondary patents on specific dosage forms or strengths
supplementary protection certificates (SPCs) where EU marketing authorizations extend exclusivity

Investment takeaway: If active-ingredient patents are already expired, the differentiator becomes formulation and method-of-use coverage that blocks generic entry or limits “label-to-label” switching.

When does Meticortelone lose exclusivity, and what are the exclusivity timing scenarios for generics?

Systemic corticosteroids rarely retain the kind of long regulatory exclusivity that drives US exclusivity-only stories for the first-to-market drugs. Instead, exclusivity outcomes generally map to:

patent expiration
SPC expiry (EU)
regulatory exclusivity attached to the specific MA (market authorization) dossier

Typical timing scenarios

Hard patent cliff: composition/formulation patents expire first, followed by generic launches within 6 to 24 months as filings and manufacturing scale complete.
SPC tail (EU-style): patent expiration occurs but SPC extends effective exclusivity in the EU until the SPC expiry date.
Regulatory-data dependence: if the product is an abridged application with reliance on older data, generic entry can follow as soon as legally permitted unless prevented by formulation/method-of-use patents.

Investment takeaway: The model should treat “generic launch risk” as an event clustered around the earliest enforceable IP or SPC end date, then refine using observed tender timelines and wholesaler stocking cycles.

What formulations are protected for Meticortelone (oral, injectable, strength-specific), and how does that change generic barriers?

For investor underwriting, formulation is usually the difference between a straightforward generic substitution and a longer legal runway. The key variables are:

dosage form (tablet, suspension, injection, etc.)
strength-specific compositions
excipient selection that changes bioavailability, stability, or manufacturing feasibility
release profile or reconstitution/handling attributes (for injectables)

Formulation patent blocking logic

Generic entrants must typically match both:

the legally relevant composition/formulation claims (if protected)
the regulated quality attributes tied to the specific MA reference product

Investment takeaway: If meticortelone is protected by strength-specific or dosage-form-specific formulation claims, generic entry can be partial, staggered, or limited to certain presentations.

What is the Orange Book status of Meticortelone, and how does that affect US generic entry risks?

US generics are primarily constrained by two layers:

Orange Book-listed patents tied to the approved drug product
court injunctions and settlement terms from Paragraph IV litigation

Investment model structure for US

Even when a drug is off-patent, US market timing depends on whether:

the Orange Book is populated with active patents
there is ongoing litigation or recent settlements
the generic seeks “carve-outs” from restricted strengths or dosage forms

Investment takeaway: For a US investment thesis, the underwriting weight sits on Orange Book listing density and the remaining life on listed patents. Without credible active listings, legal risk compresses and pricing pressure accelerates.

What Paragraph IV challenges exist for Meticortelone, and what do they imply for launch calendars?

For blockbuster-scale brands, Paragraph IV frequency is a proxy for perceived patent weakness. For established older drugs, one or two challenges can drive most of the generic competitive risk.

Launch calendar implication

If a Paragraph IV challenge triggers an early settlement, the launch is usually tied to a negotiated “carve-out” date or exclusivity window.
If the case is litigated and lost by the generic, launch is delayed until appellate resolution.

Investment takeaway: The generic entry schedule should be treated as probabilistic around (1) the earliest litigation settlement/trigger date and (2) the next viable regulatory filing and manufacturing readiness window.

How does Meticortelone compare with competing systemic corticosteroids on patent exposure and pricing power?

Competition is not only molecule-to-molecule but also presentation-to-presentation. In systemic corticosteroids, payer behavior typically drives rapid switching to lower-cost alternatives once legally possible.

Competitive dimensions that matter

injectable vs oral uptake patterns in acute care
hospital formulary and tender preferences
insurer step-therapy and reimbursement bands
safety monitoring protocols and prescriber habituation

Investment takeaway: A branded meticortelone product is usually most investable when it maintains differentiated positioning via contracts, supply reliability, or legally protected presentations. Without that, price competition usually dominates.

What patent litigation affects Meticortelone, and what settlement structures drive generic launch timing?

Where litigation exists, settlement structures tend to include:

agreed launch dates
stipulations of non-infringement for certain claims
restrictions to specific strengths or dosage forms
payment-for-delay terms (where applicable under current law)

Investment underwriting

A litigation-driven model requires mapping:

asserted patents and claim scope
court outcomes and injunction status
settlement terms and the “first generic to market” date

Investment takeaway: The valuation should reflect whether enforcement is likely to extend beyond the first generic launch or whether the settlement simply delays the inevitable without preserving meaningful share.

What is the FDA regulatory status of Meticortelone (pathway, labeling, reference product reliance)?

FDA status affects generic entry mechanics and the ability to file an ANDA or 505(b)(2)-type application.

Regulatory factors that change market risk

whether the product is approved as an NDA or other pathway
whether generics can submit with full reliance (cheap) or require additional bridging studies (costly)
label-to-label differences that influence whether a generic is therapeutically substitutable

Investment takeaway: Regulatory substitutability often drives the practical pace of switching even when some IP remains.

Which companies produce Meticortelone, who are the likely generic entrants, and how concentrated is supply?

For systemic corticosteroids, supply concentration affects:

tender leverage
stockout risk premiums
price discounts during procurement rounds

Investment signal

A limited number of suppliers can support higher gross margins even under generic pressure due to procurement dynamics.
A diversified manufacturer base accelerates price erosion.

Investment takeaway: The market share risk should be assessed on tender frequency and supplier count in each target procurement region.

What generic entry risks exist for Meticortelone (strength-specific, dosage-form specific, or label-specific)?

Generic risk for older systemic corticosteroids is often not “binary.” It tends to be segmented by:

dosage forms that have different formulation protections
strength presentations that map to separate patent claims
label indications that trigger method-of-use arguments

Common risk outcomes

Full substitution: fastest revenue compression
Partial substitution: some strengths or presentations remain brand-protected
Therapeutic non-equivalence: slower switching due to dosing or safety monitoring differences

Investment takeaway: Build a scenario tree by presentation and by the earliest enforceable patent barrier in each.

How do manufacturing/IP barriers impact generic “time to revenue” for Meticortelone?

Even after legal barriers clear, generic profitability depends on:

manufacturing yield and stability
packaging/sterility or reconstitution requirements (if injectable)
quality consistency across batches
regulatory inspection outcomes

Investment takeaway

If meticortelone’s supply requires specialized manufacturing, generic “legal clearance” may not translate immediately into market dominance. That can preserve brand revenue for longer than the patent calendar suggests.

Revenue exposure and valuation drivers: what should be modeled for Meticortelone?

A defensible valuation needs explicit linkage from IP/legal timelines to commercial impact. For meticortelone, the drivers typically include:

expected generic erosion date per geography and per presentation
market share sensitivity to price during tender cycles
margin structure (brand vs generic-like pricing)
competitor number and procurement dynamics
product lifecycle events (new formulations, supply constraints, shortages)

Scenario framework

Use three scenarios:

Bull: IP/formulation barriers delay full switching by 24 to 48 months; tender contracts protect share.
Base: partial erosion first, followed by broader substitution after the earliest expiration date.
Bear: fast generic entry across all presentations and rapid tender-based price cuts.

Key Takeaways

Meticortelone’s investment case is primarily driven by enforceable IP or SPC/formulation coverage tied to the specific dosage forms and strengths, not by broad, long-lived exclusivity typical of newer drug launches.
Generic risk should be modeled as segmented by presentation and geography, not as a single event.
US entry timing depends on Orange Book patent listings and whether any active listings remain to be cleared through litigation or settlement.
EU and other jurisdictions can extend effective exclusivity via SPC-like constructs, shifting the generic launch calendar.
Commercial fundamentals for systemic corticosteroids are highly sensitive to tendering, reimbursement, and supplier concentration, which can outperform or undercut the pure patent timetable.

FAQs

1) What dosage forms of Meticortelone face the highest generic switching risk?
The risk concentrates in the dosage forms and strengths where fewer formulation or method-of-use protections remain, enabling faster ANDA development and label-to-label substitution.

2) How do SPCs in Europe typically change generic launch timing for established corticosteroids?
SPCs can extend the effective exclusivity beyond the underlying patent expiry, delaying generic market entry even when the core compound patent is already expired.

3) What settlement terms most often determine the “first generic” date for older small molecules?
Agreed trigger/launch dates tied to patent expiry milestones, plus limitations on strengths or dosage forms, typically define the earliest permitted entry.

4) Does manufacturing complexity change the pace of generic revenue erosion?
Yes. Higher manufacturing or stability constraints can delay commercialization and slow price erosion even after legal clearance.

5) What procurement factors most influence brand survival in systemic corticosteroids?
Contract duration, formulary inclusion, tender frequency, and supplier reliability determine whether discounts are offset by volume commitments.

References (APA)

[No sources cited in the available input.]

METICORTELONE Drug Patent Profile

Which patents cover Meticortelone, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Meticortelone

AI Deep Research

Questions you can ask:

Summary for METICORTELONE

US Patents and Regulatory Information for METICORTELONE